Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06542497 · ClinicalTrials.gov registry record · Phase 3
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
A Phase 3 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
NCT06542497 is a Phase 3 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 569 participants.
The verdict
NCT06542497, a Phase 3 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
Study Summary
Safety and efficacy of POS in participants with presbyopia
Interventions
- DRUG Placebo
- DRUG 0.75% phentolamine ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06542497
The ClinicalTrials.gov registry entry for NCT06542497 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 569 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06542497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06542497 about?
NCT06542497 is a clinical study titled "Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia". Safety and efficacy of POS in participants with presbyopia
What is the current status of trial NCT06542497?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2024-08-15. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT06542497?
The interventions under investigation include: Placebo (DRUG), 0.75% phentolamine ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT06542497?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.